Enantioselective Sulfonimidamide Acylation via a Cinchona Alkaloid-Catalyzed Desymmetrization: Scope, Data Science, and Mechanistic Investigation.
Brittany C HaasNgiap-Kie LimJanis JermaksEden GasterMelody C GuoThomas C MaligJacob WerthHaiming ZhangF Dean TosteFrancis GosselinScott J MillerMatthew S SigmanPublished in: Journal of the American Chemical Society (2024)
Methods to access chiral sulfur(VI) pharmacophores are of interest in medicinal and synthetic chemistry. We report the desymmetrization of unprotected sulfonimidamides via asymmetric acylation with a cinchona-phosphinate catalyst. The desired products are formed in excellent yield and enantioselectivity with no observed bis-acylation. A data-science-driven approach to substrate scope evaluation was coupled to high throughput experimentation (HTE) to facilitate statistical modeling in order to inform mechanistic studies. Reaction kinetics, catalyst structural studies, and density functional theory (DFT) transition state analysis elucidated the turnover-limiting step to be the collapse of the tetrahedral intermediate and provided key insights into the catalyst-substrate structure-activity relationships responsible for the origin of the enantioselectivity. This study offers a reliable method for accessing enantioenriched sulfonimidamides to propel their application as pharmacophores and serves as an example of the mechanistic insight that can be gleaned from integrating data science and traditional physical organic techniques.
Keyphrases
- density functional theory
- ionic liquid
- room temperature
- electronic health record
- public health
- high throughput
- big data
- highly efficient
- reduced graphene oxide
- molecular dynamics
- physical activity
- metal organic framework
- mental health
- single cell
- case control
- gold nanoparticles
- artificial intelligence
- body composition
- clinical evaluation